文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

Lu-PSMA-617联合转移灶定向EBRT治疗转移性前列腺癌的临床结局

Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer.
PubMed 文献 · Radiother Oncol · 2026-09-15

该回顾性研究纳入88例接受镥-177 PSMA-617放射配体治疗联合转移灶定向外照射放疗的转移性前列腺癌患者,PSA50缓解率为55.7%,中位总生存期20.1个月,血液学毒性可控,支持两者联合的临床可行性与耐受性。

要点

  • 联合治疗PSA50缓解率55.7%,中位至缓解时间1.6个月。
  • 中位随访22.1个月,中位总生存期20.1个月。
  • ≥2级贫血30.7%、≥2级白细胞减少9.1%,毒性可控。

核心结论

  • 转移灶定向EBRT与全身放射配体治疗联合具有临床可行性和耐受性。
  • 既往局灶放疗不显著影响后续放射配体治疗的耐受性或疗效。

研究设计与样本

  • 回顾性分析88例转移性前列腺癌患者,接受Lu-PSMA-617与转移灶定向EBRT联合治疗。
  • 治疗时间范围为2022年6月至2025年8月。

主要发现

  • EBRT中位照射3个转移灶,最常见部位为骨(69.3%)和淋巴结(64.8%)。
  • Lu-PSMA-617的PSA50缓解率为55.7%,中位至缓解时间1.6个月。
  • 中位随访22.1个月,中位总生存期为20.1个月。
  • ≥2级贫血发生率为30.7%(含1例3级),≥2级白细胞减少为9.1%。

临床怎么用

  • 对有限体积转移性前列腺癌可考虑转移灶定向EBRT联合Lu-PSMA-617放射配体治疗。
  • 治疗期间需监测血液学毒性,尤其是贫血和白细胞减少。

局限性

  • 回顾性设计,样本量88例,需前瞻性研究确定最佳患者选择、治疗顺序和整合时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastasis-directed external beam radiation therapy (EBRT) delivered for limited-volume disease, integrated with systemic radioligand therapy, may improve long-term disease control across the spectrum of metastatic prostate cancer. We examined 88 patients with metastatic prostate cancer who received both lutetium-177 PSMA-617 (LuPSMA) radiopharmaceutical therapy and metastasis-directed external beam radiation therapy (EBRT) between June 2022 and August 2025. EBRT was delivered to a median of three metastatic sites, most commonly bone (69.3 %) and lymph nodes (64.8 %). The PSA50 response rate to LuPSMA was 55.7 %, with a median time to response of 1.6 months. With a median follow-up of 22.1 months, the median overall survival was 20.1 months. Hematologic toxicity was manageable, with grade ≥ 2 anemia in 30.7 % (including one patient with grade 3) and grade ≥ 2 leukopenia in 9.1 % of patients. These findings support the clinical feasibility and tolerability of integrating lesion-directed EBRT with systemic radioligand therapy and suggest that prior focal radiation does not meaningfully compromise tolerability or efficacy of subsequent radiopharmaceutical therapy. Prospective studies are warranted to define optimal patient selection, treatment sequencing, and timing of integration.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Adib E, Lee E, Chen YH, et al. Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer. Radiother Oncol. 2026. PMID: 42744074. doi:10.1016/j.radonc.2026.111783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。